Natural products as multidrug resistance modulators in cancer

A Kumar, V Jaitak - European journal of medicinal chemistry, 2019 - Elsevier
Cancer is a prominent cause of death globally. Currently, many drugs that are in clinical
practice are having a high prevalence of side effect and multidrug resistance. Risk of tumors …

Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer

P Joshi, RA Vishwakarma, SB Bharate - European journal of medicinal …, 2017 - Elsevier
The biggest challenge associated with cancer chemotherapy is the development of cross
multi-drug resistance to almost all anti-cancer agents upon chronic treatment. The major …

Phytochemicals: potential lead molecules for MDR reversal

B Tinoush, I Shirdel, M Wink - Frontiers in Pharmacology, 2020 - frontiersin.org
Multidrug resistance (MDR) is one of the main impediments in the treatment of cancers.
MDR cancer cells are resistant to multiple anticancer drugs. One of the major mechanisms of …

[HTML][HTML] An insight into the risk factors of brain tumors and their therapeutic interventions

S Rasheed, K Rehman, MSH Akash - Biomedicine & Pharmacotherapy, 2021 - Elsevier
Brain tumors are an abnormal growth of cells in the brain, also known as multifactorial
groups of neoplasm. Incidence rates of brain tumors increase rapidly, and it has become a …

The survivin molecule as a double‐edged sword in cellular physiologic and pathologic conditions and its role as a potential biomarker and therapeutic target in cancer

A Rafatmanesh, M Behjati, N Mobasseri… - Journal of Cellular …, 2020 - Wiley Online Library
Survivin is a member of the family of apoptosis inhibitory proteins with increased expression
level in most cancerous tissues. Evidence shows that survivin plays regulatory roles in …

Pyrimidine: A promising scaffold for optimization to develop the inhibitors of ABC transporters

ZX He, TQ Zhao, YP Gong, X Zhang, LY Ma… - European Journal of …, 2020 - Elsevier
The multidrug resistance (MDR) phenomenon in cancer cells is the major obstacle leading
to failure of chemotherapy accompanied by the feature of intractable and recurrence of …

Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro

A Sorf, J Hofman, R Kučera, F Staud… - Biochemical …, 2018 - Elsevier
Ribociclib is a novel cyclin-dependent kinase (CDK) 4 and 6 selective inhibitor that recently
gained breakthrough therapy status and global approval for advanced breast cancer …

Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic …

E Novotná, N Büküm, J Hofman, M Flaxová… - Biochemical …, 2018 - Elsevier
Members of the short-chain dehydrogenase/reductase (SDR) and aldo-keto reductase
(AKR) superfamilies mediate the reduction of anthracyclines to their less potent C-13 alcohol …

Brivanib Exhibits Potential for Pharmacokinetic Drug–Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug …

J Hofman, A Sorf, D Vagiannis, S Sucha… - Molecular …, 2019 - ACS Publications
Brivanib, a promising tyrosine kinase inhibitor, is currently undergoing advanced stages of
clinical evaluation for solid tumor therapy. In this work, we investigated possible interactions …

Recent advances on small-molecule survivin inhibitors

M Xiao, W Li - Current medicinal chemistry, 2015 - ingentaconnect.com
Survivin, a member of the inhibitor of apoptosis proteins family, is highly expressed in most
human neoplasms, but its expression is very low or undetectable in terminally differentiated …